ChondroFiller and Arthrosamid serve different knee conditions

Two injections, two different jobs in the knee

Patients comparing ChondroFiller and Arthrosamid often want to know which one is better. It is a reasonable question — but it is the wrong one, because the two injections are not competing for the same job.

ChondroFiller is an injectable collagen scaffold. Delivered as an outpatient ultrasound-guided injection, it fills a discrete hole in the cartilage at the load-bearing bone surface and recruits the body's own cells to repair that structural defect from within. Arthrosamid is a polyacrylamide hydrogel — 97.5% water — injected into the joint space, where it integrates into the synovial lining over 10–14 days and acts as a permanent mechanical cushion on the inner joint wall. One addresses a structural gap in the cartilage surface; the other cushions and calms a joint affected by diffuse osteoarthritis.

Both are delivered as ultrasound-guided outpatient injections. That procedural similarity is where the overlap ends. The question worth asking is not which treatment wins, but which matches the diagnosis — and that is a question the MRI answers, not the patient.

What ChondroFiller does inside a focal cartilage defect

The biology matters here. ChondroFiller is a Class III CE-marked injectable Type I collagen scaffold — not a filler in the cosmetic sense, but a structured matrix that sets in place within 3–5 minutes at body temperature, forming a 3D lattice inside a focal cartilage defect at the bone surface.

Once the scaffold is in position, the mechanism is what clinicians call acellular matrix-induced chondrogenesis: the collagen structure draws progenitor cells from the surrounding synovium and subchondral bone into the defect. Those cells — the patient's own — progressively populate the matrix and remodel it into cartilage-like repair tissue. The scaffold itself is gradually resorbed over one to two years. A 2025 ex vivo study provided direct mechanistic evidence of this process, measuring a 2.4-fold increase in DNA content within the scaffold by day 14, confirming active cell migration into the collagen matrix.

This mechanism works when the defect is focal and the rest of the joint is in reasonable structural health. Published clinical guidance consistently identifies the appropriate indication as a contained, full-thickness Grade III or IV cartilage lesion — typically up to 2–3 cm² — in an otherwise intact joint, most commonly in younger or active adults following trauma or a sports injury.

The treatment is delivered as an ultrasound-guided outpatient injection. Functional improvement builds progressively over six to twenty-four months as the repair tissue matures; peer-reviewed data from Simeonov (Journal of IMAB, December 2024), evaluating 17 patients with a mean age of 31 years at twelve months, reported encouraging outcomes in restoring joint congruity using Lysholm and IKDC scores.

What Arthrosamid does as a permanent joint cushion

Arthrosamid works at a different address in the joint entirely. The hydrogel — 97.5% water, 2.5% cross-linked polyacrylamide — is delivered as a single 6 mL intra-articular injection. Over the following 10–14 days it migrates into the sub-synovial tissue, integrating into the inner wall of the joint capsule rather than remaining loose in the joint fluid.

The result is a permanent, non-biodegradable cushioning layer on the capsule wall. By adding compliance to the inner joint lining, it reduces the mechanical load transmitted across the joint surface and may calm the chronic synovial inflammation that characterises established osteoarthritis. Its intended role is durable cushioning and load management, not regeneration.

That makes the indication distinctly different from ChondroFiller's. Arthrosamid is suited to patients with diffuse knee OA — Kellgren–Lawrence grade II to IV — where cartilage loss is generalised rather than focal, and where sustained symptom relief and improved day-to-day function are the primary goals.

The permanence of the material is clinically relevant to patient decision-making: unlike a biodegradable scaffold, the hydrogel remains in the joint indefinitely once integrated. Published cohort data from Bliddal et al. (J Orthop Res Ther, 2021; six-month prospective study) and Bliddal et al. (J Orthop Surg Res, 2024; twelve-month open-label follow-up) support its safety and sustained effectiveness, with registry-based data now extending to five years following a single injection.

Which patients are assessed for each treatment

The decision between these two treatments ultimately rests with imaging, not symptom description. An MRI can reveal whether cartilage loss is focal — a discrete defect at the bone surface — or diffuse, spread unevenly across joint compartments. That distinction is clinically decisive in a way that pain, stiffness, and reduced range of motion cannot be, since those symptoms present similarly across both pathologies. Weight-bearing X-rays add structural context, showing joint space narrowing and the state of surrounding bone before either pathway is considered appropriate.

Where imaging reveals a mixed picture — focal cartilage damage co-existing with broader osteoarthritic change — the two treatments are not mutually exclusive. Clinicians at several UK centres deliver both in a single outpatient session, with ChondroFiller addressing the focal structural deficit and Arthrosamid cushioning the wider joint environment. That combination, however, follows imaging confirmation of dual pathology; it is a clinical judgement, not a default.

Misapplication carries measurable consequences. A 2025 prospective controlled trial (Weninger et al., Gavin Publishers) in 25 patients with KL Grade IV OA found that ChondroFiller combined with autologous MSC concentrate significantly outperformed MSC therapy alone, suggesting that deploying ChondroFiller without biological augmentation in diffuse disease produces a weaker result. In the other direction, Arthrosamid acts on the synovial lining and cannot structurally restore a focal cartilage void — the anatomical targets are simply different.

A specialist knee assessment, bringing together clinical history, weight-bearing X-rays, and MRI, is the necessary starting point before either treatment is suitable.

When both treatments are used in the same session

For a subset of patients, the pathology-matching exercise produces two answers rather than one. A focal full-thickness defect and diffuse osteoarthritic change can — and do — coexist in the same knee, and when imaging confirms both, the clinical logic points to both treatments rather than a compromise between them.

Delivering ChondroFiller and Arthrosamid in a single outpatient session is practised at several UK specialist centres precisely because the two products work at different anatomical addresses. ChondroFiller, placed at the focal cartilage lesion on the load-bearing bone surface, acts as a regenerative scaffold — recruiting the patient's own progenitor cells to begin repair. Arthrosamid is injected intra-articularly and integrates sub-synovially, forming a cushioning layer on the joint capsule wall to reduce mechanical load and manage the inflammatory environment. Neither product duplicates the other's role, and their mechanisms do not interact.

This combination approach is not a default or an upgraded option. It is the clinical consequence of dual pathology being confirmed by assessment: two distinct problems, each with its own indicated treatment, resolved in one appointment. Suitability still requires a full specialist evaluation — including MRI and weight-bearing X-rays — to confirm that both indications are genuinely present before either product is considered.

Evidence, access, and finding the right specialist

The evidence behind both treatments is meaningful but carries comparable caveats. For ChondroFiller, Simeonov's 2024 study in the Journal of IMAB — 17 patients, mean age 31, assessed at 12 months using Lysholm and IKDC scoring — showed encouraging functional improvements, consistent with post-market follow-up data recording a mean IKDC gain of 32.4 points and good-to-excellent outcomes in more than 81% of treated patients. Arthrosamid's evidence base is larger in patient numbers: Bliddal et al. published a 6-month prospective study in 2021 and a 12-month open-label follow-up in 2024, with registry cohort data now extending to five years. Both treatments, however, share the same limitation — neither has been evaluated in a powered randomised controlled trial against surgical controls, and their respective evidence bases rely principally on non-randomised cohorts.

No head-to-head trial comparing ChondroFiller with Arthrosamid has been conducted, and the absence of one is itself informative. It reflects what the evidence does establish: these are treatments for different pathologies, addressing different anatomy through different mechanisms. The question that genuinely matters is not which product performs better overall, but which one matches what a patient's MRI confirms about their joint.

On access, neither treatment is NHS-funded or covered by major UK private insurers including Bupa and AXA; both are available through private specialist outpatient pathways. Search MSK lists clinicians across the UK who offer ChondroFiller and Arthrosamid injection — filtering by region and specialty allows patients to identify a specialist who can review their imaging and confirm which pathway, or combination of pathways, their diagnosis actually calls for.